Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Västra Hamnen Market Focus via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
2021-10-27 13:30:00
- Both revenues and costs surprised towards the negative
- Promising biosensor launch upcoming but outlook more uncertain
- We revise our valuation interval down to SEK 3.60 – 5.60 (4.30 – 6.70) per share
Heliospectra’s report for Q3 2021 came in quite a bit weaker than we had anticipated. The turnover figures are still strongly affected by the pandemic and the refocusing of the business towards food growers, a shift that has not yet started to pay off in terms of rising sales. Operating costs turned out higher than expected, primarily due to a one-off provision for future warranty claims. The upcoming launch of Heliospectra’s biosensor product could bring about a sales breakthrough, but the current slow pace in both sales and order intake makes us re-evaluate our economic scenario. Hence, we lower our valuation interval to SEK 3.60 – 5.60 per share.
The full report is available here.